Markets

Nkarta To Host Webcast On November 9 To Review Initial Clinical Data From Ntrust Program Evaluating NKX019 In Myositis And Systemic Sclerosis Being Presented At ACR Convergence 2026

Nov 6, 2026 · 04:02 PM ET· updated 26m ago

Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast on Monday, November

Why It Matters

Nkarta will share early test results for a new treatment in November. When a company presents medical data, watch if doctors seem excited or concerned about it.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NKTX1.82

+0.25 (+15.92%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.